Details

Autor(en) / Beteiligte

• Dufva, Olli
• Pölönen, Petri
• Brück, Oscar
• Keränen, Mikko A.I.
• Klievink, Jay
• Mehtonen, Juha
• Huuhtanen, Jani
• Kumar, Ashwini
• Malani, Disha
• Siitonen, Sanna
• Kankainen, Matti
• Ghimire, Bishwa
• Lahtela, Jenni
• Mattila, Pirkko
• Vähä-Koskela, Markus
• Wennerberg, Krister
• Granberg, Kirsi
• Leivonen, Suvi-Katri
• Meriranta, Leo
• Heckman, Caroline
• Leppä, Sirpa
• Nykter, Matti
• Lohi, Olli
• Heinäniemi, Merja
• Mustjoki, Satu

Titel

Immunogenomic Landscape of Hematological Malignancies

Ist Teil von

• Cancer cell, 2020-09, Vol.38 (3), p.380-399.e13

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Understanding factors that shape the immune landscape across hematological malignancies is essential for immunotherapy development. We integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investigate how immunological features are linked to cancer subtypes, genetic and epigenetic alterations, and patient survival, and validated key findings experimentally. Infiltration of cytotoxic lymphocytes was associated with TP53 and myelodysplasia-related changes in acute myeloid leukemia, and activated B cell-like phenotype and interferon-γ response in lymphoma. CIITA methylation regulating antigen presentation, cancer type-specific immune checkpoints, such as VISTA in myeloid malignancies, and variation in cancer antigen expression further contributed to immune heterogeneity and predicted survival. Our study provides a resource linking immunology with cancer subtypes and genomics in hematological malignancies. [Display omitted] •Molecular subtypes and genetics shape immune landscape in hematological malignancies•Cytotoxic T/NK cell infiltration in MDS-like AML with TP53 mutations and ABC DLBCL•Methylation changes suppress HLA genes in AML and induce cancer antigens in myeloma•Cancer type-specific targets such as VISTA in myeloid and CD70 in lymphoid cancers Dufva et al. define the immune landscape of hematological malignancies by integrating genomic, epigenomic, and transcriptomic data and describe how this influences immune cell infiltration, antigen presentation, anti-tumor immune responses, and patient outcomes.